A hybrid of thiazolidinone with the hydroxamate scaffold for developing novel histone deacetylase inhibitors with antitumor activities

被引：18

作者：

Yang, Feifei ^{[1
,2
,3
]}

Peng, Shihong ^{[1
,2
]}

Li, Yunqi ^{[1
,2
]}

Su, Liqiang ^{[1
,2
]}

Peng, Yangrui ^{[1
,2
]}

Wu, Jing ^{[1
,2
]}

Chen, Huang ^{[1
,2
]}

Liu, Mingyao ^{[1
,2
]}

Yi, Zhengfang ^{[1
,2
]}

Chen, Yihua ^{[1
,2
]}

机构：

[1] E China Normal Univ, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, Shanghai 200241, Peoples R China

[2] E China Normal Univ, Sch Life Sci, Shanghai 200241, Peoples R China

[3] Univ Jinan, Sch Biol Sci & Technol, Jinan 250022, Shandong, Peoples R China

来源：

ORGANIC & BIOMOLECULAR CHEMISTRY | 2016年 / 14卷 / 05期

基金：

中国国家自然科学基金; 高等学校博士学科点专项科研基金;

关键词：

CANCER-THERAPY; TUMOR-METASTASIS; MOLECULAR-MECHANISMS; COLONY FORMATION; HDAC INHIBITORS; DESIGN; ACETYLATION; OPTIMIZATION; PERSPECTIVES; DERIVATIVES;

D O I：

10.1039/c5ob02250a

中图分类号：

O62 [有机化学];

学科分类号：

070303 ; 081704 ;

摘要：

A series of novel histone deacetylase (HDAC) inhibitors were designed, synthesized and evaluated based on the strategies of a hybrid of the classic pharmacophore of HDAC inhibitors with the thiazolidinone scaffold. Some of the compounds showed potent HDAC1 inhibition with nM IC50 values, more importantly, compound 12i displayed much better anti-metastatic effects than vorinostat (SAHA) against migration of the A549 cell line. Further mechanism exploration implied that compound 12i may inhibit tumor metastasis via modulating the epithelial-mesenchymal transition (EMT) and upregulating the acetylation of alpha-tubulin.

引用

收藏

页码：1727 / 1735

页数：9

相关论文

共 46 条

[21] Discovery and development of SAHA as an anticancer agent [J].

Marks, P. A. .

ONCOGENE, 2007, 26 (09) :1351-1356

[22] Histone Deacetylase Inhibitors: Potential in Cancer Therapy [J].

Marks, P. A. ;

Xu, W. -S. .

JOURNAL OF CELLULAR BIOCHEMISTRY, 2009, 107 (04) :600-608

[23] Histone deacetylases and cancer: Causes and therapies [J].

Marks, PA ;

Rifkind, RA ;

Richon, VM ;

Breslow, R ;

Miller, T ;

Kelly, WK .

NATURE REVIEWS CANCER, 2001, 1 (03) :194-202

[24] Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies [J].

Matthews, Geoffrey M. ;

Mehdipour, Parinaz ;

Cluse, Leonie A. ;

Falkenberg, Katrina J. ;

Wang, Eric ;

Roth, Mareike ;

Santoro, Fabio ;

Videos, Eva ;

Stanley, Kym ;

House, Colin M. ;

Rusche, James R. ;

Vakoc, Christopher R. ;

Zuber, Johannes ;

Minucci, Saverio ;

Johnstone, Ricky W. .

BLOOD, 2015, 126 (21) :2392-2403

[25] Hybrid molecules with a dual mode of action: Dream or reality? [J].

Meunier, Bernard .

ACCOUNTS OF CHEMICAL RESEARCH, 2008, 41 (01) :69-77

[26] Histone deacetylase inhibitors [J].

Miller, TA ;

Witter, DJ ;

Belvedere, S .

JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (24) :5097-5116

[27] Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer [J].

Minucci, S ;

Pelicci, PG .

NATURE REVIEWS CANCER, 2006, 6 (01) :38-51

[28] Characterization of two classes of small molecule inhibitors of Arp2/3 complex [J].

Nolen, B. J. ;

Tomasevic, N. ;

Russell, A. ;

Pierce, D. W. ;

Jia, Z. ;

McCormick, C. D. ;

Hartman, J. ;

Sakowicz, R. ;

Pollard, T. D. .

NATURE, 2009, 460 (7258) :1031-U121

[29] Biological and Biophysical Properties of the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Are Affected by the Presence of Short Alkyl Groups on the Phenyl Ring [J].

Oger, Frederik ;

Lecorgne, Aurelien ;

Sala, Elisa ;

Nardese, Vanessa ;

Demay, Florence ;

Chevance, Soizic ;

Desravines, Danielle C. ;

Aleksandrova, Nataliia ;

Le Guevel, Remy ;

Lorenzi, Simone ;

Beccari, Andrea R. ;

Barath, Peter ;

Hart, Darren J. ;

Bondon, Arnaud ;

Carettoni, Daniele ;

Simonneaux, Gerard ;

Salbert, Gilles .

JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (05) :1937-1950

[30] Cell biology - Tubulin acetylation and cell motility [J].

Palazzo, A ;

Ackerman, B ;

Gundersen, GG .

NATURE, 2003, 421 (6920) :230-230

← 1 2 3 4 5 →